
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

